Triclosan (TCS) is a common antibacterial agent used in personal care products and many consumer products. The public is exposed to TCS as a result of its prevalence in a multitude of daily care products, waterways, and environmental samples. This is evidenced by the fact that TCS has been detected in human plasma, breast milk, and body fluids, and a large U.S. population (74.6%) had detectable TCS levels in their urine. Although it is structurally similar to other highly-regulated environmental chemicals, TCS is poorly regulated and is generally accepted as safe. Studies have increasingly linked TCS to a range of health and environmental effects; however, there are no mechanism-based studies with relevant animal models that directly link TCS exposure to negative health effects in humans. Following long-term TCS exposure, mice exhibited compensatory hepatocyte proliferation and fibrogenesis, which are accompanied by oxidative stress. Using the procarcinogen diethylnitrosamine to initiate tumorigenesis in mice, we further demonstrated that TCS, as a potent liver tumor promoter, accelerates hepatocellular carcinoma (HCC) development. TCS-treated mice exhibited a large increase in tumor multiplicity, size, and incidence compared to control mice. Increased ALT levels, histological alterations, and profound inflammatory responses following TCS treatment suggest that TCS is responsible for liver injury that leads to disrupted liver integrity and function. Another prominent feature of the TCS-treated livers is significant induction of Toll-like receptors (TLRs) 2 and 4, key molecules in the innate immunity system. Acting as sensors for pathogens, TLRs as a first-line defense against invading microorganisms detect conserved microbial components. Intestinal bacterial components are known to cause liver diseases; an emerging body of evidence also indicates that both TLR2 and TLR4 are closely linked with gut microbiota-driven liver tumorigenesis. Thus, we hypothesize that by disrupting the homeostasis of gut flora that release bacterial components into the portal vein, antibacterial TCS activates the TLR signaling through which the liver chronically deteriorates by undergoing fibrosis, inflammation, and subsequent tumorigenesis. We will examine the biochemical and cellular events as well as the composition of enteric microflora that link TLRs to TCS-induced liver pathogenesis in mice that are Tlr2-/Tlr4-heterozygous or null mice (Aim 1). The progression of HCC growth induced by TCS is still largely unknown. Since TCS-treated mice exhibited fatty liver disease (NAFLD)-like features, we therefore propose examining the effect of TCS on NAFLD progression to steatosis and to HCC by using an animal model in which high-fat diet alone in genetically modified mice can lead to the development of HCC. The hypothesis is that these mice will develop liver cancer more rapidly in animals with TCS, pointing to a synergy in tumor formation between obesity-related changes in lipogenesis and TCS-mediated hepatocellular damage and fibrosis (Aim 2). The findings originating from these studies will provide a novel opportunity to illustrate the human health complications that TCS may elicit.

Public Health Relevance

Triclosan (TCS), a broad spectrum antimicrobial agent that is commonly present in general consumer products, poses potential health risks to the public as emerging evidence links TCS to negative health effects. A mouse animal model showed that TCS promotes liver tumor growth through induction of fibrogenesis and inflammation. By using novel animal tools, the molecular and cellular events that we will define in this proposal may shed light on the role of TCS in liver tumorigenesis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21ES023906-02
Application #
8997081
Study Section
Xenobiotic and Nutrient Disposition and Action Study Section (XNDA)
Program Officer
Shreffler, Carol K
Project Start
2015-01-21
Project End
2016-12-31
Budget Start
2016-01-01
Budget End
2016-12-31
Support Year
2
Fiscal Year
2016
Total Cost
$193,750
Indirect Cost
$68,750
Name
University of California San Diego
Department
Pharmacology
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Chen, Shujuan; Lu, Wenqi; Yueh, Mei-Fei et al. (2017) Intestinal NCoR1, a regulator of epithelial cell maturation, controls neonatal hyperbilirubinemia. Proc Natl Acad Sci U S A 114:E1432-E1440
Yueh, Mei-Fei; Chen, Shujuan; Nguyen, Nghia et al. (2017) Developmental, Genetic, Dietary, and Xenobiotic Influences on Neonatal Hyperbilirubinemia. Mol Pharmacol 91:545-553
Liu, Miao; Chen, Shujuan; Yueh, Mei-Fei et al. (2016) Cadmium and arsenic override NF-?B developmental regulation of the intestinal UGT1A1 gene and control of hyperbilirubinemia. Biochem Pharmacol 110-111:37-46
Yueh, Mei-Fei; Tukey, Robert H (2016) Triclosan: A Widespread Environmental Toxicant with Many Biological Effects. Annu Rev Pharmacol Toxicol 56:251-72